申请人:DANA-FARBER CANCER INSTITUTE, INC.
公开号:US20220177443A1
公开(公告)日:2022-06-09
Disclosed are compounds and pharmaceutically acceptable salts and stereoisomers thereof that may cause degradation of various proteins e.g., IKZF2 (Helios). Also disclosed are pharmaceutical compositions containing same, and methods of making and using the compounds to treat diseases and disorders characterized or mediated by aberrant protein activity.